目前对PEAK家族成员在细胞信号通路调控和癌症治疗方面的理解。
Current understanding of PEAK family members in regulation of cellular signaling pathways and cancer therapy.
作者信息
Alavi Mana, Roudi Raheleh, D'Angelo Alberto, Sobhani Navid, Safari Fatemeh
机构信息
Department of Biology, Faculty of Science, University of Guilan, Rasht, Iran.
Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Stanford, CA, 94305, USA.
出版信息
Mol Cell Biochem. 2025 Jun;480(6):3521-3533. doi: 10.1007/s11010-025-05219-w. Epub 2025 Feb 8.
Cancer evades therapy by multiple mechanisms, leading to uncontrolled cell growth and metastasis. Targeted therapies have shown promise in treating cancer by focusing on pathways within cancer cells. The PEAK family, comprising PEAK1 (SgK269), PEAK2 (SgK223/Pragmin), and the latest addition, PEAK3 (C19orf35), plays a crucial role in modulating cellular processes. Dysregulation and hyperactivity of these proteins, through overexpression or mutations, are associated with a wide range of cancers. This review delves into the different roles of the PEAK family members in regulating cell signaling pathways and highlights their potential in cancer therapy.
癌症通过多种机制逃避治疗，导致细胞不受控制地生长和转移。靶向治疗通过关注癌细胞内的信号通路，在治疗癌症方面显示出前景。PEAK家族由PEAK1（SgK269）、PEAK2（SgK223/ Pragmin）以及最新成员PEAK3（C19orf35）组成，在调节细胞过程中起关键作用。这些蛋白质通过过表达或突变导致的失调和过度活跃与多种癌症相关。本综述深入探讨了PEAK家族成员在调节细胞信号通路中的不同作用，并强调了它们在癌症治疗中的潜力。
Zotero 插件